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Georgia Southern University
Jiann-Ping Hsu College of Public Health
BIOS 7231 – Clinical Trial Methodology
Spring 2018

Instructor:
Office:
Phone:
E-Mail Address:
Office Hours:
Web Page:
Class Meets:

Karl E. Peace
Hendrix Hall #1005
912-478-7905
kepeace@georgiasouthern.edu or peacekarl@frontier.com
Wednesday – 3:00 PM – 5:00 PM
And – By appointment, any time via email & WebEx Software
http://www.georgiasouthern.edu/~kepeace/
Wednesday – 5:00 PM-to-7:45 PM via combination of in class lectures and
electronic virtual classroom lectures via WebEx Software

-- Course schedules can be found at: http://www.collegesource.org/displayinfo/catalink.asp --

Prerequisites:

BIOS 6541; BIOS 7534; or by permission of instructor

VISTA Address:

Via MyGeorgiaSouthern on GSU Home Page

Catalog Description:

Students are introduced to regulatory, scientific, statistical and
practical aspects of methods inherent in design, monitoring and
analysis of clinical trials. Clinical trials in many areas of drug
development are presented, discussed and critiqued.

Required Textbook:

Clinical Trial Methodology by Karl E. Peace and Din Chen
Series: Chapman & Hall/CRC Biostatistics Series
Cat. #: C9179
ISBN: 9781584889175
ISBN 10: 1584889179
Publication Date: July 19, 2010
Number of Pages: 420
The course is presented using power points. Students are
provided copies of the power points on a Flash Drive.

Secondary Texts:
Chen D, Peace KE (2017): Clinical Trial Data Analysis using R and SAS; Chapman &
Hall/CRC, Taylor and Francis Group; ISBN: 978-1-4987-7982-4
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Chen D, Peace KE (2010): Clinical Trial Data Analysis using R; Chapman & Hall/CRC, Taylor
and Francis Group; ISBN: 978-1-4398-4020-7
Chen, D, Peace KE (2013): Applied Meta-Analysis using R. Chapman & Hall/CRC, Taylor and
Francis Group; 13: 978-1-4665-0599-5; May 2013.
Chen D, Sun J, Peace KE [Editors and Author contributors] (2012): Interval-Censored Time-toEvent Data: Methods and Applications"; Chapman & Hall/CRC,
Taylor and Francis Group; Published July 2012.
Peace, K. E. [Editor and Author contributor] (2008): Design and Analysis of Clinical Trials with
Time to Event Endpoints; Chapman & Hall/CRC Taylor and Francis
Group; Boca, ISBN 978-1-4200-6639-5.
Peace, K. E. [Editor and Author contributor] (1992): Biopharmaceutical Sequential Statistical
Applications. Marcel Dekker, Inc., New York, ISBN 0-8247-8628-9.
Peace, K. E. [Editor and Author contributor] (1990): Statistical Issues in Pharmaceutical Drug
Development. Marcel Dekker, Inc., New York, ISBN 0-8247-8290-9.
Peace, K.E. [Editor and author contributor] (1988): Biopharmaceutical Statistics in Drug
Development. Marcel Dekker, Inc., New York, ISBN 0-8247-7798-0.
Biostatistics Student Learning Outcomes (BSLO):
Cross-cutting:
1. Demonstrate proficiency and effectiveness in the communication of core public health
principles and practices, both oral and written.
2. Demonstrate proficiency in the integration of the core public health disciplines
(Biostatistics, Epidemiology, Environmental Health, Health Policy/Management, and
Social/Behavioral Science) in practice and research.
3. Demonstrate proficiency in problem solving, critical thinking, and public health
leadership.
MPH Biostatistics Concentration:
1. Provide the biostatistica l co mpone nts of the de sign of a public he alth or biome dica l
e xpe rime nt by: clarifying the rese arch obje ctives or que stions; de te rmining data and
e ndpoints to be co lle cte d appropria te for the obje ctive s; translating the obje ctive s
into biostatis tica l que stions via hypothe sis te sting or co nfide nce inte rval
frame works; de te rmining the appropria te sa mple size ; and writing the statis tica l
analysis se ction of the e xpe rime nt.
2. Apply appropria te statistica l analysis me thods using SAS to analyze both ca te gorica l
and quantitative data.
3. Deve lop writte n and oral reports to co mmunica te e ffe ctive ly to rese arch inve stigators
pivotal asp e cts of a study, including its de sign, obje ctive s, data, analysis me thods,
resu lts, and co nclusions e nsuring that resu lts and co nclusions are valid and reliable
and address the re se arch obje ctive s.
4. Create a co llaborative e nvironme nt for working on writte n and oral reports and
deve loping critica l thinking skills .
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5. De scribe key co nce pts and the ory unde rlying biostatistica l me thodology use d in
probability and infe rential, analytica l, and de scriptive statistics.
Course Objectives:
1. Translate public health and biomedical research objectives into statistical hypotheses
(BSLO 1, 3, 4, 5)
2. Design public health and biomedical research clinical trials (BSLO 1, 3, 4, 5)
3. Develop Statistical Analysis Sections for public health and biomedical research Protocols
(BSLO 1, 2, 3, 4, 5)
4. Explain the requirements for good protocol development for public health and biomedical
research clinical trials (BSLO 1, 2, 3, 4, 5)
5. Apply common statistical descriptive and inferential analysis methods to data collected in
public health and biomedical research clinical trials (BSLO 1, 2, 3, 4, 5)
6. Describe methodological alternatives to commonly used statistical methods used in
public health and biomedical research clinical trials when analysis assumptions are not
met (BSLO 2, 3, 5)
7. Interpret results of statistical analyses of data collected from public health and biomedical
clinical trials (BSLO 1, 2, 3, 4, 5)
8. Develop written and oral presentations based on statistical analyses of public health and
biomedical research clinical trials, for both public health professionals and educated lay
audiences (BSLO 1, 2, 3, 4, 5)
9. Identify key federal regulation ‘governing’ the conduct of clinical trials (BSLO 1, 3, 5)
10. Explain the importance of the numbers of patients in clinical trials (BSLO 1, 2, 3, 4, 5)
11. Explain the importance of monitoring adverse experiences in clinical trials (BSLO 1, 2,
3, 5)
12. Describe methods for monitoring adverse experiences in clinical trials (BSLO 1, 2, 3, 5)
13. Explain how data from multicentre clinical trials may be ‘pooled’ (BSLO 1, 2, 3, 5)
14. Describe the issues in group sequential clinical trials (BSLO 1, 2, 3, 5)
Instructional Methods: Class meetings will be a combination of lecture and class discussion in
a blended format (In classroom, and virtual classroom via WebES in real time). Lectures for
classes conducted via WebEX will be recorded so that students can replay them as a way of
review. After each class, students are expected to send to Dr. Peace 1 – 2 questions about
material covered in the class. The questions and their answers will be compiled into a Word
document and sent to students before the next class. The questions and their answers will be
discussed by Dr. Peace at the beginning of the next class. Homework assignments, class
participation and the final examination constitute the basis of student grades. Students are
expected to make use of office hours (in office or via WebEX) and email contact to discuss
concepts or difficulties they may have. In addition, they may seek the assistance of the GA.
Daily Study Log: Students are required to keep a daily computerized study log. The study log
should have a column for the date, a column to identify topic of study, a column to identify the
time of beginning study, a column to identify the ending time of study, and a column to identify
the amount of time spent in studying the topic.
Final Examination: April 27, 2018 Last day of classes
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April 30- May 04, 2018 Final exams
Grading: Weighting of assignments for purposes of grading will be as follows:
Final Exam (objectives 1-14, integrated)……………60%
Assignment (objectives 1-14, individually)……. …..30%
Class Participation (objectives 1-14, individually)…10%
____
Total Possible
100%
The following point scale will be utilized in grading:
90% - 100%
80% - 90%
70% - 80%
60% - 70%

A
B
C
D

There are times when extraordinary circumstances occur (e.g., serious
illness, death in the family, etc.). In such circumstances, and/or if you
need additional time to satisfactorily complete any course requirement,
please consult with the instructor within a reasonable amount of time.
Academic Misconduct: As a student registered at this University, it is expected that you will
adhere to only the strictest standards of conduct. It is recommended
that you review the latest edition of the Student Conduct Code book, as
well as the latest Undergraduate & Graduate Catalog to familiarize
yourself with the University’s policies in this regard. Your continued
enrollment in this course is an implied contract between you and the
instructor on this issue; from this point forward, it is assumed that you
will conduct yourself appropriately.
Academic integrity relates to the appropriate use of intellectual
property. The syllabus, lecture notes, and all materials presented
and/or distributed during this course are protected by copyright law.
Students are authorized to take notes in class, but that authorization
extends only to making one set of notes for personal (and no other)
use. As such, students are not authorized to sell, license, commercially
publish, distribute, transmit, display, or record notes in or from class
without the express written permission of the instructor.
Academic Handbook:

Students are expected to abide by the Academic Handbook, located at
http://students.georgiasouthern.edu/conduct/. Your failure to comply
with any part of this Handbook may be a violation and thus, you may
receive an F in the course and/or be referred for disciplinary action.

University Calendar:

The University Calendar for the semester can be found at:
http://students.georgiasouthern.edu/registrar/calendar.htm
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Attendance Policy:

Federal regulations require attendance be verified prior to distribution
of financial aid allotments. Students are expected to attend each
class meeting.

One Final Note:

The contents of this syllabus are as complete and accurate as possible.
The instructor reserves the right to make any changes necessary to the
syllabus and course material. The instructor will make every effort to
inform students of changes as they occur. It is the responsibility of the
student to know what changes have been made in order to successfully
complete the requirements of the course.

Overview of the Content to be Covered During the Semester:
Module I: An Overview of the Regulation of Pharmaceuticals
Module II: An Overview of the Processes of Discovery, Basic Research, Clinical Development
and Manufacturing in Pharmaceutical Development
Module III: Biostatistical Aspects of Clinical Drug Development
A. The Components of a Protocol
B. Statistical Analysis Section of a Clinical Trial Protocol
Module IV: Bioavailability & Bioequivalence of Pharmaceutical Formulations
Module V: Interim Analyses: p-Value and Power Computations in Group Sequential Trials
Module VI: Design & Analysis of Pivotal Clinical Trials to Assess the Efficacy of Drugs to
Treat Panic Disorder
Module VII: Design & Clinical Trials in the Prevention of NSAID Induced Gastric Ulceration
Module VIII: Design & Analysis of Clinical Trials in the development of H2-Receptor
Antagonist Drugs in the Optimal Treatment of Duodenal Ulcers
Module XIX: Design & Analysis of Clinical Trials of Antianginal Drugs
Module X: Enrichment Design & Analysis of Clinical Trials of Drugs to Treat Alzheimer’s
disease
Module XI: Analysis and Interpretation of Cancer Clinical Trials
Module XII: Monitoring Adverse Experiences in Clinical Drug Development
Module XIII: The Pooling of Data from Multicenter Clinical Trials
Module XIV: The Importance of Numbers (of Patients) in Cancer Clinical Trials
Module XV: Statistical Analysis of Dose Response Trials
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Student Information (CTM Class):
Print Full Name

email address

Pledge to spend enough time
to master material? Circle one.

1. ________________

________________

Yes

No

Undecided

2. ________________

________________

Yes

No

Undecided

3. ________________

________________

Yes

No

Undecided

4. ________________

________________

Yes

No

Undecided

5. ________________

________________

Yes

No

Undecided

6. ________________

________________

Yes

No

Undecided

7. ________________

________________

Yes

No

Undecided

8. ________________

________________

Yes

No

Undecided

9. ________________

________________

Yes

No

Undecided

10. ________________

________________

Yes

No

Undecided

11. ________________

________________

Yes

No

Undecided

12. ________________

________________

Yes

No

Undecided
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